首页 › 非小细胞肺癌 › 佛罗里达州 › West Palm Beach
West Palm Beach FL 非小细胞肺癌临床试验
13项针对 非小细胞肺癌的研究正在 West Palm Beach及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
招募中2 期
- Florida Cancer Specialists - East /ID# 271993, West Palm Beach
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
招募中3 期
- Florida Cancer Specialists & Research Institute - East, West Palm Beach
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
招募中3 期
- Florida Cancer Specialists - East, West Palm Beach
- Florida Cancer Specialists, Palm Beach Gardens · 距离 9 英里
- Florida Cancer Specialists, Wellington · 距离 12 英里
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
招募中2 期
- Florida Cancer Specialists & Research Institute, West Palm Beach
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
招募中3 期
- Florida Cancer Specialists East, West Palm Beach
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
招募中3 期
- Research Site, West Palm Beach
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
招募中3 期
- Florida Cancer Specialists - East, West Palm Beach
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
招募中3 期
- Clinical Study Site, West Palm Beach
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
招募中2/3 期
- SCRI - Florida Cancer Specialists - West Palm Beach, West Palm Beach
- Local Institution - 007-926-A, Wellington · 距离 12 英里
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
招募中1/2 期
- Florida Cancer Specialists - EAST - SCRI - PPDS, West Palm Beach
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
招募中3 期
- Florida Cancer Specialists - EAST - SCRI - PPDS, West Palm Beach
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
招募中3 期
- Research Site, West Palm Beach
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
招募中1/2 期
- USOR Florida Cancer Specialists East, West Palm Beach
其他城市的 非小细胞肺癌试验
- Houston, TX145 项研究
- New York City, NY121 项研究
- Arlington, VA104 项研究
- Nashville, TN97 项研究
- Boston, MA90 项研究
- Los Angeles, CA87 项研究
- St. Louis, MO73 项研究
- Chicago, IL61 项研究
- Baltimore, MD60 项研究
- San Antonio, TX59 项研究
- Columbus, OH57 项研究
- Washington, DC55 项研究
West Palm Beach的其他研究
- 阿尔茨海默病13 项研究
- 肥胖症11 项研究
- 卵巢癌11 项研究
- 超重9 项研究
- 子宫内膜癌8 项研究
- 精神分裂症7 项研究
- 心力衰竭7 项研究
- 2型糖尿病7 项研究
- 心血管疾病7 项研究
- 重度抑郁症7 项研究
- 慢性阻塞性肺病6 项研究
- HIV6 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。